Nasdaq:SHPH
Shuttle Pharmaceuticals Holdings, Inc.
A clinical-stage biotech firm leveraging proprietary technology to address rare disease markets with a lean operational model.
Key Metrics
Investment Thesis
Bull Case
SHPH offers investors early exposure to a potential breakthrough therapy in the lucrative rare disease sector with a relatively small market cap. The positive cash flow from financing suggests management is actively managing liquidity through equity raises, potentially at lower dilution costs than peers. If any assets or partnerships are monetized, the current asset base of $2.5M could provide a valuation floor.
Bear Case
The stock carries extreme downside risk given the lack of commercial revenue and a deepening net loss trend from -$3.0M in 2022 to -$9.5M in 2024. With total liabilities exceeding $1.8M and a retained earnings deficit of nearly $35M, the company's solvency is precarious without imminent successful clinical data or major funding rounds.
About Shuttle Pharmaceuticals Holdings, Inc.
Shuttle Pharmaceuticals Holdings, Inc. (SHPH) is a biopharmaceutical company focused on developing novel therapeutics for rare diseases, primarily operating in the United States with a pipeline targeting unmet medical needs.
Analysis
Management Discussion
Management executed a net cash burn of $7.3M in the latest period, driven by research and development expenses of $3.6M and general administrative costs of $1.4M. Despite generating positive cash flow from financing activities of $3.8M through share issuances and investing inflows, the company continues to accumulate a significant deficit, reflecting the capital-intensive nature of its clinical-stage operations.
Industry Overview
The biopharmaceutical industry for rare diseases is characterized by high failure rates in clinical trials but offers substantial market exclusivity and pricing power due to orphan drug designations. Investors in this space must evaluate pipeline potential against the reality of limited cash reserves and the constant threat of dilution from capital raising events.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| Operating Expenses | $2.6M | $5.9M | $7.7M |
| Operating Income | $-2.6M | $-5.9M | $-7.7M |
| R&D | $1.5M | $3.5M | $3.6M |
| G&A | $199.0K | $1.0M | $1.4M |
| Stock-Based Comp | $404.0K | $182.0K | $259.7K |
| Depreciation | $6.0K | $6.8K | $5.5K |
| Other OpEx | $866.8K | $1.3M | $2.7M |
| Non-Operating Income | $-474.2K | $-700.3K | $0 |
| Interest Income | — | $79.1K | $38.1K |
| Pre-Tax Income | $-3.0M | $-6.6M | $-7.7M |
| Income Tax | $0 | $0 | $1.8M |
| Continuing Ops | $-3.0M | $-6.6M | $-9.5M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-3.0M | $-6.6M | $-9.5M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-3.0M | $-6.6M | $-9.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $8.6M | $5.6M | $2.2M |
| Cash & Equivalents | $8.4M | $2.6M | $1.9M |
| Marketable Securities | — | $2.9M | — |
| Other Current Assets | $161.1K | $129.4K | $290.8K |
| Long-Term Assets | $75.2K | $358.7K | $295.4K |
| PP&E (Net) | $12.6K | $24.8K | $19.4K |
| Operating Leases | $56.1K | $333.9K | $276.0K |
| Other LT Assets | $6.5K | $0 | $0 |
| Total Assets | $8.7M | $6.0M | $2.5M |
| Current Liabilities | $975.7K | $1.0M | $1.5M |
| Current Leases | $62.8K | $52.5K | $60.9K |
| Other Current Liab | $912.9K | $989.8K | $1.5M |
| Long-Term Liabilities | $0 | $853.7K | $263.4K |
| LT Operating Leases | — | $304.1K | $238.1K |
| Other LT Liab | — | $549.6K | $25.3K |
| Total Liabilities | $975.7K | $1.9M | $1.8M |
| Shareholders' Equity | $7.7M | $4.1M | $709.2K |
| Paid-In Capital | — | $19.5M | $35.3M |
| Retained Earnings | $-8.9M | $-15.5M | $-34.6M |
| Total L&E | $8.7M | $6.0M | $2.5M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-3.0M | $-6.6M | $-9.5M |
| Non-Cash Adjustments | $560.6K | $769.3K | $1.8M |
| Working Capital Changes | $-242.6K | $242.3K | $459.9K |
| Cash from Operations | $-2.7M | $-5.6M | $-7.3M |
| Capital Expenditures | — | $19.0K | — |
| Cash from Investing | $0 | $-2.8M | $2.9M |
| Debt Repayments | — | — | $59.7K |
| Cash from Financing | $10.6M | $2.6M | $3.8M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $7.9M | $-5.8M | $-656.3K |
| Beginning Cash | $504.7K | $8.4M | $2.6M |
| Ending Cash | $8.4M | $2.6M | $1.9M |
Frequently Asked Questions
How does Shuttle Pharmaceuticals Holdings, Inc. make money?
The company operates primarily through its biopharmaceutical research and development segment, focusing on drug discovery and late-stage clinical trials for rare disease indications. All current revenue streams are derived from strategic collaborations and grants rather than commercial product sales, resulting in zero reported gross profit.
What are the main risks for SHPH?
SHPH faces significant liquidity risk with cash reserves of $1.9M against an annual operating burn rate of $7.3M, necessitating frequent capital raises. The company has no commercial revenue or approved products, making it entirely dependent on future clinical trial success and external funding. High dilution risk exists due to a history of substantial share issuances ($4.0M recently) and a retained earnings deficit of $34.6M.
What is SHPH's competitive advantage?
The company possesses a specialized expertise in identifying and developing therapies for orphan diseases with high unmet medical needs. Its lean capital structure minimizes overhead costs, allowing for efficient resource allocation toward high-value research and development projects.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.